August 14, 2025 a 11:43 am
PFE: Fundamental Ratio Analysis - Pfizer Inc.
Pfizer Inc. operates in the healthcare sector, specifically in drug manufacturing. The stock presents a stable outlook with moderate growth expectations. Investors should consider both market conditions and Pfizer's strategic collaborations to evaluate its potential comprehensively.
Fundamental Rating
The fundamental data reveals a moderate overall performance with specific strengths highlighted.
| Category | Score | Visualization |
|---|---|---|
| Discounted Cash Flow | 5 | |
| Return on Equity | 4 | |
| Return on Assets | 4 | |
| Debt to Equity | 1 | |
| Price to Earnings | 2 | |
| Price to Book | 3 |
Historical Rating
The comparison of historical scores illustrates relative consistency in Pfizer's financial health.
| Date | Overall | DCF | ROE | ROA | Debt/Eq | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2025-08-13 | 3 | 5 | 4 | 4 | 1 | 2 | 3 |
| Historical | 0 | 5 | 4 | 4 | 1 | 2 | 3 |
Analyst Price Targets
Analysts have set a uniform price target for Pfizer's shares, indicating stable near-term expectations.
| High | Low | Median | Consensus |
|---|---|---|---|
| 24 | 24 | 24 | 24 |
Analyst Sentiment
The current consensus towards Pfizer's stock is predominantly hold, with a cautious approach to investment.
| Recommendation | Count | Distribution |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 15 | |
| Hold | 21 | |
| Sell | 1 | |
| Strong Sell | 0 |
Conclusion
Pfizer Inc. presents itself as a stable investment with moderate potential for growth, primarily driven by its diverse pharmaceutical offerings and collaborative endeavors. While the fundamental ratios indicate some financial strength, the heavy emphasis on 'hold' ratings by analysts suggests careful consideration before positioning. The company's historical consistency, particularly in key financial metrics, aligns well with such outlooks. Investors should stay informed regarding any strategic shifts or market developments that might affect Pfizer's standing.